AstraZeneca PLC (AZN) Tax Rate: 17.49%
Is AstraZeneca PLC’s tax rate high or low?
AstraZeneca PLC's tax rate of 17.49% is 42% below its 5-year average of 30.25%, near the low end of its 5-year range (-31.67%–143.40%).
4.11% below its 12-month average of 18.24%.
AZN Tax Rate Chart
AZN Average Tax Rate Chart
AZN Current vs Average Tax Rate Chart
AZN Tax Rate Metrics
TAX RATE
17.49%
TAX RATE AVG TTM
18.24%
TAX RATE AVG 3Y
4.60%
TAX RATE AVG 5Y
30.25%
TAX RATE AVG 10Y
16.60%
TAX RATE AVG 15Y
16.76%
TAX RATE AVG 20Y
19.78%
CURRENT VS TTM AVG
-4.11%
CURRENT VS 3Y AVG
+280.01%
CURRENT VS 5Y AVG
-42.19%
CURRENT VS 10Y AVG
+5.33%
CURRENT VS 15Y AVG
+4.34%
CURRENT VS 20Y AVG
-11.59%
AstraZeneca PLC Tax Rate Formula & Definition
Tax rate measures income tax expense as a percentage of income before tax. It helps compare tax efficiency and identify unusual tax effects.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
AstraZeneca PLC Tax Rate FAQ
- What is the tax rate for AstraZeneca PLC (AZN)?
- The tax rate for AZN stock is 17.49%.
- Is AstraZeneca PLC's tax rate high or low?
- AstraZeneca PLC's tax rate of 17.49% is 42% below its 5-year average of 30.25%, near the low end of its 5-year range (-31.67%–143.40%).
- What is the TTM average tax rate for AstraZeneca PLC (AZN)?
- The TTM average tax rate for AZN stock is 18.24%.
- What is the 3Y average tax rate for AstraZeneca PLC (AZN)?
- The 3Y average tax rate for AZN stock is 4.60%.
- What is the 5Y average tax rate for AstraZeneca PLC (AZN)?
- The 5Y average tax rate for AZN stock is 30.25%.
- What is the 10Y average tax rate for AstraZeneca PLC (AZN)?
- The 10Y average tax rate for AZN stock is 16.60%.
- What is the 15Y average tax rate for AstraZeneca PLC (AZN)?
- The 15Y average tax rate for AZN stock is 16.76%.
- What is the 20Y average tax rate for AstraZeneca PLC (AZN)?
- The 20Y average tax rate for AZN stock is 19.78%.
AstraZeneca PLC Tax Rate History
| DATE | TAX RATE |
|---|---|
| 2025-12-31 | 17.49% |
| 2024-12-31 | 18.99% |
| 2023-12-31 | 13.60% |
| 2022-12-31 | -31.67% |
| 2021-12-31 | 143.40% |
| 2020-12-31 | 19.71% |
| 2019-12-31 | 20.74% |
| 2018-12-31 | -2.86% |
| 2017-12-31 | -28.78% |
| 2016-12-31 | 4.11% |
| 2015-12-31 | 7.92% |
| 2014-12-31 | 0.88% |
| 2013-12-31 | 21.30% |
| 2012-12-31 | 18.00% |
| 2011-12-31 | 18.99% |
| 2010-12-31 | 26.38% |
| 2009-12-31 | 30.19% |
| 2008-12-31 | 29.39% |
| 2007-12-31 | 29.51% |
| 2006-12-31 | 29.03% |
| 2005-12-31 | 29.14% |
| 2004-12-31 | 23.97% |
| 2003-12-31 | 25.34% |
| 2002-12-31 | 26.98% |
| 2001-12-31 | 27.08% |
| 2000-12-31 | 33.75% |
| 1999-12-31 | 29.47% |
| 1998-12-31 | 28.91% |
| 1997-12-31 | 31.91% |
| 1996-12-31 | 32.82% |
Related Metrics
About AstraZeneca PLC
AstraZeneca PLC operates as a global biopharmaceutical leader, dedicated to the entire process of bringing prescription medicines to market, from their initial discovery and development through manufacturing and commercialization. The company's extensive portfolio of treatments, including prominent examples like Tagrisso, Farxiga, and Symbicort, addresses critical areas such as cardiovascular, renal, metabolic, and oncological conditions. Furthermore, it provides essential solutions for COVID-19 and various rare diseases, with products like Vaxzevria and Soliris. AstraZeneca engages with primary and specialty care physicians worldwide, facilitating distribution through a robust network of representatives and local offices across the United Kingdom, continental Europe, the Americas, Asia, Africa, and Australasia. The firm actively drives innovation through strategic collaborations, partnering with entities such as Neurimmune AG for the development and commercialization of NI006, BenevolentAI for systemic lupus erythematosus drug discovery, Lunit for AI-powered digital pathology risk assessment in NSCLC, and Absci Corporation for AI-driven oncology target identification. Founded in 1992, the company was initially known as Zeneca Group PLC, subsequently rebranding to AstraZeneca PLC in April 1999, and maintains its headquarters in Cambridge, United Kingdom.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- CEO
- Pascal Claude Roland Soriot